» Articles » PMID: 27713038

Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review

Overview
Specialty Gastroenterology
Date 2016 Oct 8
PMID 27713038
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

High-throughput sequencing analysis has accelerated searches for genes associated with risk for colorectal cancer (CRC); germline mutations in NTHL1, RPS20, FANCM, FAN1, TP53, BUB1, BUB3, LRP6, and PTPN12 have been recently proposed to increase CRC risk. We attempted to validate the association between variants in these genes and development of CRC in a systematic review of 11 publications, using sequence data from 863 familial CRC cases and 1604 individuals without CRC (controls). All cases were diagnosed at an age of 55 years or younger and did not carry mutations in an established CRC predisposition gene. We found sufficient evidence for NTHL1 to be considered a CRC predisposition gene-members of 3 unrelated Dutch families were homozygous for inactivating p.Gln90Ter mutations; a Canadian woman with polyposis, CRC, and multiple tumors was reported to be heterozygous for the inactivating NTHL1 p.Gln90Ter/c.709+1G>A mutations; and a man with polyposis was reported to carry p.Gln90Ter/p.Gln287Ter; whereas no inactivating homozygous or compound heterozygous mutations were detected in controls. Variants that disrupted RPS20 were detected in a Finnish family with early-onset CRC (p.Val50SerfsTer23), a 39-year old individual with metachronous CRC (p.Leu61GlufsTer11 mutation), and a 41-year-old individual with CRC (missense p.Val54Leu), but not in controls. We therefore found published evidence to support the association between variants in NTHL1 and RPS20 with CRC, but not of other recently reported CRC susceptibility variants. We urge the research community to adopt rigorous statistical and biological approaches coupled with independent replication before making claims of pathogenicity.

Citing Articles

New RPS20 gene variant in colorectal cancer diagnosis: insight from a large series of patients.

Amiot J, Gubeljak L, Fontaine A, Smith D, Mortemousque I, Parodi N Fam Cancer. 2025; 24(1):22.

PMID: 39920491 DOI: 10.1007/s10689-025-00446-y.


Genetic Testing of Japanese Patients with Serrated Polyposis Syndrome: A Multicentric Study.

Takao A, Yamaguchi T, Eguchi H, Okazaki Y, Ishikawa H, Akagi K J Anus Rectum Colon. 2024; 8(4):348-355.

PMID: 39473720 PMC: 11513425. DOI: 10.23922/jarc.2024-030.


Genetics, diet, microbiota, and metabolome: partners in crime for colon carcinogenesis.

La Vecchia M, Sala G, Sculco M, Aspesi A, Dianzani I Clin Exp Med. 2024; 24(1):248.

PMID: 39470880 PMC: 11522171. DOI: 10.1007/s10238-024-01505-x.


Anti-Cancer Mechanisms of Diarylpentanoid MS17 (1,5-Bis(2-hydroxyphenyl)-1,4-pentadiene-3-one) in Human Colon Cancer Cells: A Proteomics Approach.

Hon K, Zainal Abidin S, Abas F, Othman I, Naidu R Int J Mol Sci. 2024; 25(6).

PMID: 38542474 PMC: 10970808. DOI: 10.3390/ijms25063503.


Deficiency of the ribosomal protein uS10 (RPS20) reorganizes human cells translatome according to the abundance, CDS length and GC content of mRNAs.

Tian Y, Babaylova E, Gopanenko A, Tupikin A, Kabilov M, Malygin A Open Biol. 2024; 14(1):230366.

PMID: 38290548 PMC: 10827436. DOI: 10.1098/rsob.230366.


References
1.
Segui N, Mina L, Lazaro C, Sanz-Pamplona R, Pons T, Navarro M . Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. Gastroenterology. 2015; 149(3):563-6. DOI: 10.1053/j.gastro.2015.05.056. View

2.
Smith C, Naven M, Harris R, Colley J, West H, Li N . Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Hum Mutat. 2013; 34(7):1026-34. DOI: 10.1002/humu.22333. View

3.
Timofeeva M, Kinnersley B, Farrington S, Whiffin N, Palles C, Svinti V . Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer. Sci Rep. 2015; 5:16286. PMC: 4639776. DOI: 10.1038/srep16286. View

4.
Chubb D, Broderick P, Dobbins S, Frampton M, Kinnersley B, Penegar S . Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016; 7:11883. PMC: 4917884. DOI: 10.1038/ncomms11883. View

5.
Yurgelun M, Masciari S, Joshi V, Mercado R, Lindor N, Gallinger S . Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol. 2015; 1(2):214-21. PMC: 4465271. DOI: 10.1001/jamaoncol.2015.0197. View